# Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy

> **NCT01990352** · PHASE2 · TERMINATED · sponsor: **University of Arizona** · enrollment: 24 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT01990352
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-05
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The PI determined that study specimens being obtained did not yield sufficient data to analyze the prespecified outcome measures and decided to terminate the study prior to meeting enrollment goals.
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01990352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01990352, "Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01990352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*